Sun Pharma highlights strong ESG performance, financial growth for FY 2024-25

Sun Pharmaceutical Industries Limited released its ESG Overview for FY 2024-25, reporting a 41% energy reliance on renewable sources and a 25% reduction in absolute water consumption compared to its 2020 baseline. The company also achieved a ~21% reduction in absolute carbon emissions and a 43% decrease in specific intensity for Scope 1 and 2 carbon emissions against the same baseline. Hazardous waste diverted from disposal reached 37% through recycling, while 96% of non-hazardous waste was diverted. The company reported zero fatalities and INR 1,424 Mn in CSR spend, impacting over 1 Mn lives in India.

The company's workforce grew by 6,978 new hires, with gender diversity reaching 18.6% in the total workforce. Corporate governance highlights include a 92.9% average Board meeting attendance and 62.5% independent Board directors. Sun Pharma reported INR 169,230 Mn in India sales and INR 162,403 Mn in USA sales for FY 2024-25, maintaining its position as the largest pharma company in the Indian market. R&D investments accounted for 6.2% of revenues, targeting 6-8% annually by 2026. The company recorded zero environmental non-compliance issues and no non-compliance incidents related to product information or marketing communications during the reporting period.